Stockreport

argenx Reports First Quarter 2022 Financial Results and Provides Business Update

argenx SE - American Depositary Shares  (ARGX) 
PDF $21.2 million in VYVGART® (efgartigimod alfa-fcab) net product sales during initial quarter of U.S. commercial launchMet primary endpoint in Phase 3 ADVANCE trial of V [Read more]